Category: biotech

.Editas Medicines has signed a $238 million biobucks treaty to mix Genevant Science’s lipid nanoparticle (LNP) specialist along with the gene treatment biotech’s fledgling in

.Versus the backdrop of a Cas9 patent war that rejects to die, Editas Medicine is cashing in a piece of the licensing legal rights from

.Compass Pathways’ journey to phase 3 psychedelic anxiety records is taking a lot longer than expected. Along with the tests overwhelming through months, the biotech

.Tip has mentioned phase 3 data on its near-approval pain medicine prospect suzetrigine, shedding light on just how the non-opioid pain reliever integrates with ibuprofen

.Mandarin the hormone insulin producer Gan &amp Lee Pharmaceuticals is actually falling to the obesity world along with an injectable GLP-1 agonist that beat Novo

.China-based Minghui Drug has connected its own thyroid eye condition procedure to a decline in eye protruding in a little period 1b/2 medical test.The research

.Cassava Sciences has actually accepted to pay for $40 million to settle an investigation right into claims it created deceptive claims concerning phase 2b records

.Gritstone bio has actually brought in bankers to check out “prospective value-maximizing strategies” after its own stage 2 colon cancer injection data disappointed the loose

.Capricor Rehabs is taking a success lap for their phase 2 Duchenne muscular dystrophy (DMD) trial. At three years, the San Diego-based company’s cell treatment

.RNA biotech CAMP4 Therapies has actually defined plans for a $67 thousand IPO, along with inflammation-focused Upstream Biography pegging its very own dreams at $182